GSK Seeks Marketing Partner (India)
This article was originally published in PharmAsia News
Executive Summary
As part of its attempt to enhance its therapeutic coverage in cardiovascular, diabetes and other high-growth segments, the Indian division of GlaxoSmithKline is searching for brand in-licensing opportunities to market products for lifestyle-related diseases. GlaxoSmithKline Pharmaceuticals Managing Director Hasit B. Joshipura has confirmed that the company is hunting "for partners and we are in discussions with a couple of companies." The announcement marks a departure for GSK's portfolio, which has consisted mainly of traditional therapeutic segments. The redirection will include rolling out products from GSK's portfolio, Joshipura added. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.